Across all lines of therapy in our study, patients with HER2 IHC0/HR-positive and HER2-low/HR-positive BC had similar and better median OS compared to patients with HER2 IHC0/HR-negative and HER2-low/HR-negative BC. The gene discussed is ERBB2; the disease is breast cancer.